Extended-release wax-matrix nicotinic acid supports cardiovascular health, preliminary study shows
Highlights
- Preliminary pilot trial (n=13 adults)
- Support for lipid metabolism and vascular health
- Effective dosage is 1,500 mg/day for 2 years
Summary
The aim of this preliminary study was to examine the effect of extended-release, wax-matrix nicotinic acid (WMNA) treatment on blood lipids and atherosclerotic progression in patients with coronary artery disease (CAD).
The study involved 13 patients, aged 39 to 60 years, with documented CAD and primary hyperlipidemia. The patients received WMNA (1,500 mg/day) for up to 2 years.
WMNA treatment resulted in a reduction in total cholesterol by 10.3% and low-density lipoprotein (LDL) cholesterol by 13.1% and an increase in high-density lipoprotein (HDL) cholesterol by 15.2%. In 75% of patients, stabilization of atherosclerosis was observed after 2 years of WMNA treatment. Half of the patients experienced increased levels of liver transaminases, however discontinuation of treatment was not necessary.
These findings suggest that long-term use of WMNA helps inhibit the progression of atherosclerosis in patients with CAD.
